Tumour immune cell infiltration and survival after platinum-based chemotherapy in high-grade serous ovarian cancer subtypes: A gene expression-based computational study.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 31911269.
- Also identified by DOI 10.1016/j.ebiom.2019.102602 and PMC identifier 6948169.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Increasing evidence supports that the immune infiltration of tumours is associated with prognosis. Here, we sought to assess the relevance of the cellular composition of the immune infiltrate to survival after platinum-based chemotherapy amongst patients with high-grade serous ovarian cancer and evaluate these effects by molecular subtype. We searched publicly available databases and identified 13 studies with more than 2000 patients. We estimated the proportions of 22 immune cell subsets by using a computational approach (CIBERSORT). Then, we investigated the associations between each immune cell subset and progression-free survival (PFS) and overall survival (OS), with cellular proportions modelled as quartiles. A high fraction of M1 [hazard ratio (HR) = 0.92, 95% confidence interval (CI) = 0.86-0.99] and M0 (HR = 0.93, 95% CI = 0.87-0.99) macrophages emerged as the most closely associated with favourable OS. Neutrophils were associated with poor OS (HR = 1.06, 95% CI = 1.00-1.13) and PFS (HR = 1.10, 95% CI = 1.02-1.13). Amongst the immunoreactive tumours, the M0 macrophages and the CD8+ T cells were associated with improved OS, whereas the M2 macrophages conferred worse OS. Interestingly, PD-1 was associated with good OS (HR=0.89, 95% CI = 0.80-1.00) and PFS (HR=0.89, 95% CI = 0.79-1.01) in this subtype. Four subgroups of tumours with distinct survival patterns were identified using immune cell proportions with unsupervised clustering. Further investigations of the quantitative cellular immune infiltrations in tumours may contribute to therapeutic advances.
Medical subject headings
- Computational Biology
- Cystadenocarcinoma, Serous
- Gene Expression Regulation, Neoplastic
- Ovarian Neoplasms
- Platinum